biostudies-literatureUnknown136(5)Handa NAstellas PharmaPfizerPfizer Inc<h4>Objectives</h4>To evaluate the longitudinal transcriptomic changes that occurred over time in patients from the ENACT trial (ClinicalTrials.gov identifier: NCT02799745). ENACT evaluated patients with low- or intermediate-risk prostate cancer, comparing the efficacy and safety of enzalutamide plus active surveillance (AS) to AS alone.<h4>Patients and methods</h4>Gene-expression profiling was conducted using the Decipher Genomic Resource for Intelligent Discovery (GRID) platform (Veracyte, Inc.) on 131 patient samples (enzalutamide plus AS: n = 57; AS alone: n = 74) collected at screening, Year 1, and Year 2. Pre-defined GRID signatures were analysed for associations with biological and clinical features, including immune activity, treatment sensitivity, metastatic risk, and molecular suBJU international920-929https://www.ebi.ac.uk/biostudies/studies/S-EPMC12522525biostudies-literatureTranscriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.PMC12522525Shore NDRoss AHanda NDavicioni ERussell DCooperberg MRProudfoot JASchaeffer EMZhao XIwata KKLiu YElsouda DKuperman GfalseTranscriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.<h4>Objectives</h4>To evaluate the longitudinal transcriptomic changes that occurred over time in patients from the ENACT trial (ClinicalTrials.gov identifier: NCT02799745). ENACT evaluated patients with low- or intermediate-risk prostate cancer, comparing the efficacy and safety of enzalutamide plus active surveillance (AS) to AS alone.<h4>Patients and methods</h4>Gene-expression profiling was conducted using the Decipher Genomic Resource for Intelligent Discovery (GRID) platform (Veracyte, Inc.) on 131 patient samples (enzalutamide plus AS: n = 57; AS alone: n = 74) collected at screening, Year 1, and Year 2. Pre-defined GRID signatures were analysed for associations with biological and clinical features, including immune activity, treatment sensitivity, metastatic risk, and molecular su2025-01-01T00:00:00Z2025 Nov2026-05-09T03:23:07.842Z2026-05-09T03:12:18.503ZS-EPMC125225254074200210.1111/bju.16861